Real-world retrospective study on the efficacy and safety of anti-IgE therapy combined with rush immunotherapy in allergic asthma
Regarding the safety of dust mite rush immunotherapy for allergic asthma, Omalizumab significantly reduces the incidence of SRs in high-risk populations (sIgE grades 3-6 and sIgE/T-IgE ≥10%), whereas it demonstrates limited efficacy in low-risk subgroups (sIgE grades 1-2 and sIgE/T-IgE <10%).
Authors
- Zhao‐Ji Meng
- Siqin Wang (ORCID: https://orcid.org/0000-0003-3601-7827)
- Yinzi Jin (ORCID: https://orcid.org/0000-0003-0634-3955)
- Dan Liu (ORCID: https://orcid.org/0000-0001-8078-4674)
- Wenchao Zhang (ORCID: https://orcid.org/0000-0001-8985-2186)
- Xianghua Lin
- Wenjin Du
- Wei-Li Guo (ORCID: https://orcid.org/0000-0002-3952-2389)
- Qiuxing Zhang
Institutions
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2025-12-15
- DOI
- https://doi.org/10.3389/falgy.2025.1717446
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 0.00